No article notes available at this time.
• Provides a real-world benchmark of response rates across different systemic agents used for desmoid tumors, useful context when newer targeted therapies are being evaluated. • Supports systemic therapy as a viable alternative to morbid or disabling surgery in cases where resection would carry significant functional cost — relevant when counseling patients on treatment sequencing. • Identifies Gardner syndrome and nodular tumor morphology as factors linked to disease behavior, which may help set expectations for progression risk in individual patients.
No article notes available at this time.
• Provides a real-world benchmark of response rates across different systemic agents used for desmoid tumors, useful context when newer targeted therapies are being evaluated. • Supports systemic therapy as a viable alternative to morbid or disabling surgery in cases where resection would carry significant functional cost — relevant when counseling patients on treatment sequencing. • Identifies Gardner syndrome and nodular tumor morphology as factors linked to disease behavior, which may help set expectations for progression risk in individual patients.